Wedbush analyst David Nierengarten reiterated an Outperform rating for Telix Pharmaceuticals, maintaining a price target of $22. The rating affirmation signals continued confidence in the company's performance trajectory.

Analyst Rating and Price Target

The research note from Wedbush reinforces the positive outlook on the stock. The following table details the current analyst stance:

Telix Pharmaceuticals has secured alignment from the United States Food and Drug Administration (FDA) to advance the ProstACT Global Phase 3 trial into the U.S. following a successful Type B meeting. The FDA confirmed that safety data from Part 1 of the study is sufficient to enable progression into Part 2, which involves administering TLX591-Tx in two doses, 14 days apart, in combination with standard-of-care therapies. This agreement establishes a consistent framework for study execution as enrollment expands internationally and into the U.S.

The FDA and Telix achieved alignment on the Part 2 clinical trial protocol, statistical analysis plan, and ongoing safety monitoring plan across three randomized standard-of-care combination cohorts: abiraterone, enzalutamide, or docetaxel. Part 2 continues to recruit in jurisdictions where the study has regulatory approval, including Australia, New Zealand, Canada, Türkiye, and the United Kingdom. Regulatory approval has also been received to commence the study in China, Singapore, and South Korea.

David N. Cade, MD, Group Chief Medical Officer at Telix, stated that the outcome enables the submission of an Investigational New Drug (IND) amendment for the initiation of Part 2 in the U.S. He noted that enrollment remains strong in regions where recruitment is open. The IND amendment will also be aligned with a pending regulatory submission to initiate the ProstACT Global study in Europe.

Neeraj Agarwal, MD, Professor of Medicine at Huntsman Cancer Institute and ProstACT Global Principal Investigator, highlighted the potential of TLX591-Tx to redefine radiopharmaceutical therapy integration. He emphasized that the complete treatment course is delivered over approximately two weeks, allowing physicians to layer it into existing regimens with minimal interruption. This flexibility may help preserve future treatment options for patients with metastatic prostate cancer.

ProstACT Global Trial Details

ProstACT Global is an international, multicenter trial divided into two parts. Part 1 was a safety and dosimetry lead-in with 36 patients, which is now complete. Part 2 is a 2:1 randomized global expansion with an overall target enrollment of approximately 490 patients.

Eligible patients must have confirmed progressive metastatic castration-resistant prostate cancer (mCRPC) assessed with a 68Ga-PSMA-11 PET imaging agent following prior treatment with one androgen receptor pathway inhibitor (ARPI). The antibody-based approach of TLX591-Tx demonstrates differentiated targeting and pharmacology compared to other PSMA-targeted small molecule radioligand therapies. Long-term follow-up has not observed significant acute or delayed kidney toxicity, as the agent is hepatically excreted. Additionally, TLX591-Tx shows minimal salivary and lacrimal gland uptake, reducing the prevalence of dry mouth and dry eye.